Xlife Sciences AG
Develops and commercializes early-stage life sciences research projects.
XLS | SW
Overview
Corporate Details
- ISIN(s):
- CH0461929603 (+1 more)
- LEI:
- 984500AH590BE88BB517
- Country:
- Switzerland
- Address:
- Talacker 35, 8001 Zürich
Description
Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2022-12-01 01:00 |
Portfoliogesellschaft Lysatpharma und Joint-Venture Novaxomx starten Forschung …
|
German | HTML • 10.8 KB | ||
| 2022-11-28 07:00 |
alytas therapeutics collaborates with spin-off from the German Diabetes Center
|
English | HTML • 11.0 KB | ||
| 2022-11-28 01:00 |
alytas therapeutics collaborates with spin-off from the German Diabetes Center
|
English | HTML • 9.3 KB | ||
| 2022-11-28 01:00 |
Portfoliogesellschaft alytas therapeutics kooperiert mit Spin-off des Deutschen…
|
German | HTML • 9.5 KB | ||
| 2022-11-21 07:01 |
Xlife Sciences initiates a review of strategic options
|
English | HTML • 10.8 KB | ||
| 2022-11-21 01:00 |
Xlife Sciences initiates a review of strategic options
|
English | HTML • 9.1 KB | ||
| 2022-11-21 01:00 |
Xlife Sciences leitet eine Prüfung strategischer Optionen ein
|
German | HTML • 10.1 KB | ||
| 2022-11-01 07:00 |
ProcCluster from portfolio company inflamed pharma granted US patent
|
English | HTML • 11.7 KB | ||
| 2022-11-01 01:00 |
ProcCluster® from portfolio company inflamed pharma granted US patent
|
English | HTML • 10.1 KB | ||
| 2022-11-01 01:00 |
ProcCluster® von Portfoliogesellschaft inflamed pharma erhält US-Patent
|
German | HTML • 11.1 KB | ||
| 2022-09-28 07:01 |
Xlife Sciences with pleasing progress in the first half of 2022
|
English | HTML • 21.0 KB | ||
| 2022-09-28 02:00 |
Xlife Sciences with pleasing progress in the first half of 2022
|
English | HTML • 19.3 KB | ||
| 2022-09-28 02:00 |
Xlife Sciences mit erfreulichen Fortschritten im 1. Halbjahr 2022
|
German | HTML • 22.0 KB | ||
| 2022-09-26 07:00 |
Project company Laxxon Medical achieves major milestone
|
English | HTML • 11.3 KB | ||
| 2022-09-26 02:00 |
Project company Laxxon Medical achieves major milestone
|
English | HTML • 9.4 KB |
Automate Your Workflow. Get a real-time feed of all Xlife Sciences AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xlife Sciences AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xlife Sciences AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-15 | N/A | Executive member | Buy | None | 6,000.00 CHF |
| 2022-06-15 | N/A | Executive member | Buy | None | 3,000.00 CHF |
| 2022-06-14 | N/A | Executive member | Buy | None | 15,500.00 CHF |
| 2022-06-10 | N/A | Executive member | Buy | None | 6,728.90 CHF |
| 2022-06-07 | N/A | Executive member | Buy | None | 34,800.00 CHF |
| 2022-06-03 | N/A | Executive member | Buy | None | 3,540.00 CHF |
| 2022-05-24 | N/A | Executive member | Buy | None | 3,400.00 CHF |
| 2022-05-17 | N/A | Executive member | Buy | None | 10,794.20 CHF |
| 2022-05-13 | N/A | Executive member | Buy | None | 3,690.00 CHF |
| 2022-05-10 | N/A | Executive member | Buy | None | 1,935.00 CHF |
Peer Companies
